<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393367</url>
  </required_header>
  <id_info>
    <org_study_id>2006-8-4875</org_study_id>
    <nct_id>NCT00393367</nct_id>
  </id_info>
  <brief_title>Budesonide Inhalation Suspension for Acute Asthma in Children</brief_title>
  <official_title>Budesonide Inhalation Suspension for Acute Asthma in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of budesonide inhalation
      suspension (BIS) to the standard therapy of albuterol, ipratropium bromide, and systemic
      corticosteroids (SCS) for moderate to severe asthma flares in children reduces asthma
      severity more rapidly than standard therapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context: Acute asthma is a leading cause of emergency department (ED) visits and
      hospitalizations. Although standard therapy for acute asthma includes systemic
      corticosteroids (SCS), these drugs take many hours to have an effect. Recent studies
      demonstrate that inhaled corticosteroids (ICS) may improve patients' asthma severity more
      rapidly than SCS and may decrease hospitalizations. Only a few small studies have evaluated
      ICS added to standard therapy for acute asthma in children.

      Objective: To determine if adding the nebulized steroid budesonide to standard therapy
      including SCS improves patients' asthma severity faster than standard therapy alone and leads
      to fewer hospitalizations.

      Study Design/Setting/Participants: A double-blind, randomized, controlled trial of budesonide
      inhalation suspension (BIS) versus placebo for children 2 to 18 years of age who present to a
      tertiary care, urban pediatric ED with a moderate to severe asthma flare.

      Intervention: Participants will receive standard therapy including SCS, albuterol, and
      ipratropium bromide and will be randomly assigned to also receive either nebulized BIS or
      saline.

      Study Measures: Differences in asthma scores, vital signs, and the need for hospitalization
      will be compared between treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Change in Asthma Score 2 Hours After Intervention</measure>
    <time_frame>Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator</time_frame>
    <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Asthma Score at 2 Hours</measure>
    <time_frame>Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator</time_frame>
    <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Hospitalized</measure>
    <time_frame>within 4 hours after the budesonide/albuterol intervention or saline/albuterol placebo</time_frame>
    <description>The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Heart Rate</measure>
    <time_frame>From the initial heart rate to heart rate 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
    <description>Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Respiratory Rate.</measure>
    <time_frame>Initial rate, minus rate taken 2 hours after budesonide/albuterol intervention or saline/albuterol comparator</time_frame>
    <description>Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation.</measure>
    <time_frame>2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator</time_frame>
    <description>Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Remaining in the Severe Asthma Category</measure>
    <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
    <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category</measure>
    <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
    <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Moving From the Severe Asthma to Mild Asthma Category</measure>
    <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
    <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse / Readmission Numbers.</measure>
    <time_frame>within 5 days of ED visit</time_frame>
    <description>Participants admitted to the hospital within 5 days of the ED visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (Non-serious).</measure>
    <time_frame>within 30 days of the ED visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>0-5 days</time_frame>
    <description>Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Asthma</condition>
  <condition>Acute Asthma</condition>
  <condition>Reactive Airway Exacerbation</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide Inhalaiton Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg</intervention_name>
    <description>Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.</description>
    <arm_group_label>Budesonide Inhalaiton Suspension</arm_group_label>
    <other_name>Pulmicort</other_name>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone, prednisone, or methylprednisolone</intervention_name>
    <description>All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_label>Budesonide Inhalaiton Suspension</arm_group_label>
    <other_name>Prednisolone</other_name>
    <other_name>prednisone</other_name>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol, ipratropium bromide</intervention_name>
    <description>While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_label>Budesonide Inhalaiton Suspension</arm_group_label>
    <other_name>Albuterol</other_name>
    <other_name>Atrovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide</intervention_name>
    <description>500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_label>Budesonide Inhalaiton Suspension</arm_group_label>
    <other_name>Atrovent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chief complaint of &quot;respiratory distress&quot;, &quot;asthma&quot;, &quot;trouble breathing&quot;, or &quot;reactive
             airway disease&quot;

          -  Males or females age 2 to 18 years

          -  Weight greater than or equal to 10 kilograms

          -  Two or more prior Emergency Department or primary care visits for asthma or reactive
             airway disease

          -  Identified in triage as either &quot;acute&quot; or &quot;critical&quot;

          -  Asthma score of 8 or greater

          -  Systemic corticosteroid prescribed in the Emergency Department

          -  English-speaking parent/guardian present

          -  Parental/guardian permission (informed consent) and if appropriate, child assent

        Exclusion Criteria:

          -  Systemic corticosteroid use in the last 30 days

          -  Chronic lung diseases including cystic fibrosis

          -  Sickle cell anemia

          -  Immunodeficiency

          -  Cardiac disease requiring surgery or medications

          -  Adverse drug reaction or allergy to budesonide, albuterol, ipratropium bromide,
             prednisone, prednisolone, or methylprednisolone

          -  Known renal or hepatic dysfunction

          -  Exposure to varicella in the last 21 days

          -  Impending respiratory failure requiring positive pressure ventilation

          -  Altered level of consciousness

          -  Suspected foreign body aspiration or croup

          -  Prior enrollment in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia J Mollen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan D. Upham, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of New Mexico Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia Emergency Department</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2003;(3):CD002308. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD002308.</citation>
    <PMID>12917930</PMID>
  </reference>
  <reference>
    <citation>Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med. 1998 Oct 8;339(15):1030-5.</citation>
    <PMID>9761804</PMID>
  </reference>
  <reference>
    <citation>Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med. 1998 Mar;5(3):209-13.</citation>
    <PMID>9523927</PMID>
  </reference>
  <reference>
    <citation>Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999 Aug;88(8):835-40.</citation>
    <PMID>10503681</PMID>
  </reference>
  <reference>
    <citation>Scarfone RJ, Loiselle JM, Wiley JF 2nd, Decker JM, Henretig FM, Joffe MD. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med. 1995 Oct;26(4):480-6.</citation>
    <PMID>7574132</PMID>
  </reference>
  <reference>
    <citation>Nuhoglu Y, Atas E, Nuhoglu C, Iscan M, Ozcay S. Acute effect of nebulized budesonide in asthmatic children. J Investig Allergol Clin Immunol. 2005;15(3):197-200.</citation>
    <PMID>16261956</PMID>
  </reference>
  <reference>
    <citation>Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, Alothman G, Tennis O, Canny G. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000 Sep 7;343(10):689-94.</citation>
    <PMID>10974132</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2006</study_first_posted>
  <results_first_submitted>April 9, 2010</results_first_submitted>
  <results_first_submitted_qc>June 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2011</results_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Acute</keyword>
  <keyword>Treatment</keyword>
  <keyword>Children</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Inhaled corticosteroid</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Budesonide inhalation suspension</keyword>
  <keyword>Asthma score</keyword>
  <keyword>Emergency</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Asthma flare</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Randomized clinical trial</keyword>
  <keyword>Randomized trial</keyword>
  <keyword>Pulmonary index score</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Moderate asthma</keyword>
  <keyword>Severe asthma</keyword>
  <keyword>Mixing budesonide</keyword>
  <keyword>Budesonide admixture</keyword>
  <keyword>Albuterol</keyword>
  <keyword>Continuous albuterol</keyword>
  <keyword>Ipratropium bromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Budesonide Inhalation Suspension (BIS)</title>
          <description>standardized treatment with nebulized Budesonide Inhalation Suspension (BIS)</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Saline)</title>
          <description>standardized treatment with nebulized saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide Inhalation Suspension (BIS)</title>
          <description>standardized treatment with nebulized Budesonide Inhalation Suspension (BIS)</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Saline)</title>
          <description>standardized treatment with nebulized saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="3.9"/>
                    <measurement group_id="B2" value="6.3" spread="4.0"/>
                    <measurement group_id="B3" value="6.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Change in Asthma Score 2 Hours After Intervention</title>
        <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
        <time_frame>Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator</time_frame>
        <population>88 of the 91 patients randomized to budesonide were evaluable for the primary outcome (1 was discharged home, 1 had no 2 hour score, and 1 did not have a valid initial score). 81 of the 89 patients randomized to placebo were evaluable (1 inadvertently received standard therapy, 2 withdrew, and 5 were admitted before a 2 hour score evaluation).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Asthma Score 2 Hours After Intervention</title>
          <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
          <population>88 of the 91 patients randomized to budesonide were evaluable for the primary outcome (1 was discharged home, 1 had no 2 hour score, and 1 did not have a valid initial score). 81 of the 89 patients randomized to placebo were evaluable (1 inadvertently received standard therapy, 2 withdrew, and 5 were admitted before a 2 hour score evaluation).</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-8" upper_limit="2"/>
                    <measurement group_id="O2" value="-3" lower_limit="-8" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>The difference in median improvement between treatment groups was expected to be greater than 2.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Hospitalized</title>
        <description>The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician.</description>
        <time_frame>within 4 hours after the budesonide/albuterol intervention or saline/albuterol placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
            <description>standardized treatment with nebulized Budesonide Inhalation Suspension (BIS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Saline)</title>
            <description>standardized treatment with nebulized saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Hospitalized</title>
          <description>The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Heart Rate</title>
        <description>Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol</description>
        <time_frame>From the initial heart rate to heart rate 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Heart Rate</title>
          <description>Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7" upper_limit="17"/>
                    <measurement group_id="O2" value="13" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Respiratory Rate.</title>
        <description>Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator.</description>
        <time_frame>Initial rate, minus rate taken 2 hours after budesonide/albuterol intervention or saline/albuterol comparator</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Respiratory Rate.</title>
          <description>Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator.</description>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-8" upper_limit="-3"/>
                    <measurement group_id="O2" value="-6" lower_limit="-8" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation.</title>
        <description>Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment.</description>
        <time_frame>2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation.</title>
          <description>Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment.</description>
          <units>Percent Hemoglobin Saturation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Remaining in the Severe Asthma Category</title>
        <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
        <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
        <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who remained in that category 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Remaining in the Severe Asthma Category</title>
          <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
          <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who remained in that category 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category</title>
        <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
        <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
        <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who moved to the moderate asthma category (Asthma Score 8-11) 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category</title>
          <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
          <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who moved to the moderate asthma category (Asthma Score 8-11) 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Moving From the Severe Asthma to Mild Asthma Category</title>
        <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
        <time_frame>From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator</time_frame>
        <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who moved to the moderate asthma category (Asthma Score 8-11) 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Moving From the Severe Asthma to Mild Asthma Category</title>
          <description>Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator.</description>
          <population>Number of patients who presented in the severe asthma category (Asthma Score 12-15) who moved to the moderate asthma category (Asthma Score 8-11) 2 hours after either the intervention with budesonide/albuterol or saline/albuterol comparator.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse / Readmission Numbers.</title>
        <description>Participants admitted to the hospital within 5 days of the ED visit</description>
        <time_frame>within 5 days of ED visit</time_frame>
        <population>89 of the 91 patients randomized to BIS were available for follow-up. 85 of the 89 patients randomized to placebo were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Relapse / Readmission Numbers.</title>
          <description>Participants admitted to the hospital within 5 days of the ED visit</description>
          <population>89 of the 91 patients randomized to BIS were available for follow-up. 85 of the 89 patients randomized to placebo were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Asthma Score at 2 Hours</title>
        <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
        <time_frame>Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator</time_frame>
        <population>88 of the 91 patients randomized to budesonide were evaluable for the primary outcome (1 was discharged home, 1 had no 2 hour score, and 1 did not have a valid initial score). 81 of the 89 patients randomized to placebo were evaluable (1 inadvertently received standard therapy, 2 withdrew, and 5 were admitted before a 2 hour score evaluation).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Asthma Score at 2 Hours</title>
          <description>The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator.</description>
          <population>88 of the 91 patients randomized to budesonide were evaluable for the primary outcome (1 was discharged home, 1 had no 2 hour score, and 1 did not have a valid initial score). 81 of the 89 patients randomized to placebo were evaluable (1 inadvertently received standard therapy, 2 withdrew, and 5 were admitted before a 2 hour score evaluation).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-3.4" upper_limit="-2.4"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-3.5" upper_limit="-2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (Non-serious).</title>
        <time_frame>within 30 days of the ED visit</time_frame>
        <population>Of the 180 patients randomized, 91 were to BIS, 89 were to placebo. Two patients were lost to follow-up in the BIS group and 4 in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (Non-serious).</title>
          <population>Of the 180 patients randomized, 91 were to BIS, 89 were to placebo. Two patients were lost to follow-up in the BIS group and 4 in the placebo group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rhinorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Serious Adverse Events</description>
        <time_frame>0-5 days</time_frame>
        <population>89 of the 91 patients randomized to BIS were available for follow-up. 85 of the 89 patients randomized to placebo were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Inhalation Suspension (BIS)</title>
            <description>standardized treatment with nebulized Budesonide Inhalation Suspension (BIS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Saline)</title>
            <description>standardized treatment with nebulized saline</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Serious Adverse Events</description>
          <population>89 of the 91 patients randomized to BIS were available for follow-up. 85 of the 89 patients randomized to placebo were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Return within 5 days with hosptial admission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased level of care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Budesonide Inhalation Suspension (BIS)</title>
          <description>standardized treatment with nebulized Budesonide Inhalation Suspension (BIS)</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Saline)</title>
          <description>standardized treatment with nebulized saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization within 5 days of Emergency Department discharge home</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Increased level of care</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>emesis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinorrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cynthia J. Mollen</name_or_title>
      <organization>The Children's Hospital of Philadelphia</organization>
      <phone>215-590-4410</phone>
      <email>mollenc@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

